TRUDI: TDXD+Durva in HER2+/Low IBC
NCT05795101
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer. The names of the study drugs involved in this study are: Trastuzumab deruxtecan Durvalumab
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Invasive Breast Cancer
- Inflammatory Breast Cancer Stage III
- HER2-positive Breast Cancer
- HER2 Low Breast Adenocarcinoma
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Filipa Lynce, MD
- Last updated on ClinicalTrials.gov
- October 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 2
- Brigham and Women's Hospital · Boston, MA
- Dana Farber Cancer Institute · Boston, MA
Texas · 1
- University of Texas MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.